Key Takeaways for Jazz Pharmaceuticals Stock as of August 2026
- Record Quarter: Jazz Pharmaceuticals posted record Q2 revenue of $1.21B, up 16% YoY.
- Revenue Outlook Lifted: Jazz Pharmaceuticals raised full-year 2026 revenue guidance to $4.60B-$4.75B and now expects Xywav to grow by double digits, up from a prior flat-to-mid-single-digit forecast, with rare sleep revenue guided to $2.025B-$2.125B.
- Zepzelca’s Reacceleration: Zepzelca net sales jumped 42% YoY to $106M as first-line maintenance use grew to 30-40% of U.S. sales, offsetting the expected decline in its second-line business.
- CFO Flags Generic Delay: Phil Johnson said the guidance raise reflects “extremely strong execution in the field” that is producing a “very slow uptake” of generic high-sodium oxybate.
Jazz Pharmaceuticals’ Beats and Raises, But the Real Catalyst Is Still Ahead
Jazz Pharmaceuticals (JAZZ) posted record second-quarter 2026 revenue of $1.21 billion on its August 3 earnings call, a 16% jump from the same period last year that pushed management to raise full-year guidance for the second time this year. Oncology sales climbed 32% year over year, and that segment now carries as much weight in the growth story as the rare sleep franchise that built the company.
Xywav, the low-sodium oxybate that anchors Jazz’s sleep business, grew net sales 13% to $471 million even as generic competitors entered the market this year. The company added roughly 525 net patients in the quarter, the highest addition in a year, lifting total active patients to about 17,125, up 12% year over year. That performance forced a guidance rewrite. Jazz now expects Xywav to grow by double digits in 2026, up from a prior forecast of flat to mid-single-digit growth, and lifted rare sleep revenue guidance to a range of $2.025 billion to $2.125 billion.
CFO Phil Johnson explained the shift directly on the Q2 earnings call: “The revised guidance really comes down to extremely strong execution in the field that’s led to this unique benefit that Xywav has resonating with physicians and patients, which we believe is most likely leading to the very slow uptake that we’re seeing of generic high sodium oxybate.” Total company revenue guidance now sits at $4.60 billion to $4.75 billion for the year. Jazz’s cash position, $2.2 billion after generating $824 million of operating cash flow in the first half, funds both the sleep franchise defense and the oncology buildout underway.
Zepzelca supplied the sharpest swing in the quarter. Net sales jumped 42% year over year to $106 million as the drug’s first-line maintenance use, now 30% to 40% of United States sales, more than offset the expected decline of its older second-line business. Jazz plans to file a labeling supplement in the third quarter to remove that second-line indication, a move that will accelerate the erosion but leaves the larger first-line opportunity untouched.
The bigger swing factor arrives August 25, when the FDA is due to rule on zanidatamab in first-line HER2-positive metastatic gastroesophageal adenocarcinoma. Sold as Ziihera in its approved second-line bile duct cancer indication, zanidatamab has already captured more than 50% of that market, and management says over 90% of the physicians who treat gastroesophageal cancer overlap with doctors already prescribing it there. A Phase III trial published in the New England Journal of Medicine showed a 26.4 month median overall survival for the zanidatamab combination, more than seven months longer than the trastuzumab control arm.
TIKR Values Jazz Pharmaceuticals Stock at $246, Below Where It Trades Today
TIKR’s mid-case model values Jazz Pharmaceuticals at $246 by December 2030, a target that implies a 2% loss from the current price of $252 over the next 4.4 years, or a 1% annualized decline.
That return profile puts Jazz Pharmaceuticals stock in negative territory, a rare place for a company that just raised full-year revenue guidance and posted double-digit growth across three separate franchises.
The model’s downside case reflects how much of Jazz’s near-term story already sits in the price: the Xywav guidance raise, the Zepzelca reacceleration and the pending zanidatamab approval are already known to the market rather than surprises still to come, and each carries execution risk that could cap further upside. If the August 25 decision or the pending Horizon GEA-01 doublet data disappoint, the stock has little cushion built into TIKR’s base case.
Should You Invest in Jazz Pharmaceuticals plc?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Jazz Pharmaceuticals plc stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Jazz Pharmaceuticals plc alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze JAZZ stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
